ETHZilla, formerly 180 Life Sciences Corp. (Nasdaq: ATNF), has pivoted from biotech R&D into a blockchain-focused corporate treasury strategy. The company now centers its operations on accumulating and holding Ethereum (ETH) as a primary asset, aiming to leverage ETH’s long-term value through secure custody, staking, and on-chain yield opportunities. Backed by substantial institutional funding, ETHZilla positions itself as a publicly traded vehicle offering investors direct exposure to Ethereum without personal custody risks.